What GQ Life Sciences does

GQ Life Sciences, Inc. was a Boston-based private life science information and search company founded in 2001 that built GenomeQuest, a specialized enterprise software platform for biological sequence intellectual property search. The platform aggregated a database of more than 694 million sequences spanning both patent and non-patent sources and provided specialized search tools including Enhanced Keyword in Context and SEQ ID Highlighting, enabling comprehensive prior art, patent novelty, and freedom-to-operate analysis for biological IP. The company served three primary vertical segments: pharmaceutical and biotechnology companies requiring IP sequence search for drug development and R&D protection; government patent offices (including IP Australia, IP New Zealand, Danish Patent Office, and Norwegian Industrial Property Office) requiring sequence search for patent examination; and IP law firms and legal service providers (including Cooley, Fish & Richardson, Choate Hall & Stewart, Wolf Greenfield, and others) supporting patent prosecution and litigation.

The company operated an enterprise software licensing revenue model based on recurring subscription contracts with annual billing cadence, supported by a global enterprise field sales motion with quote-based pricing accessible only through 'Request a demo' and 'Request pricing' engagements. The company was funded through three disclosed rounds between 2005 and 2009 totaling approximately $11.2M from investors including Cross Atlantic Capital Partners, Mosaix Ventures, Activate Venture Partners, and Societe Generale Asset Management. GQ Life Sciences was acquired by Aptean, a strategic operating company in vertical enterprise software, with the GenomeQuest product rebranded as Aptean GenomeQuest and integrated into Aptean's IP Search solutions portfolio. Following the acquisition, the company no longer operates as an independent entity; the original gqlifesciences.com domain redirects to the Aptean product page.

Name

GQ Life Sciences

Website

https://gqlifesciences.com

Company type

Private

Founded year

2001

Operating status

Acquired

Headcount range

11–50 employees

Short description

GQ Life Sciences built GenomeQuest, an enterprise biological IP search platform covering 694+ million patent and non-patent sequences, serving pharmaceutical companies, government patent offices, and IP law firms. The company was acquired by Aptean and now operates as Aptean GenomeQuest.

Ownership category

akta.pro rank

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Enterprise Software Licensing: Enterprise software licensing model for IP sequence search solution targeting pharmaceutical, biotechnology, and IP law organizations.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

GQ Life Sciences develops and licenses GenomeQuest (now Aptean GenomeQuest), an enterprise biological IP search platform that indexes 694+ million sequences from both patent and non-patent sources. The software enables pharmaceutical, biotechnology, patent office, and IP law firm users to conduct comprehensive sequence-domain prior art, novelty, and freedom-to-operate searches with features such as Enhanced Keyword in Context and SEQ ID Highlighting.

Product overview

GQ Life Sciences redirects to Aptean GenomeQuest, a single unified product offering for comprehensive biological IP sequence search. The platform provides access to 694+ million sequences across patent and non-patent databases, featuring enhanced keyword context display and sequence ID highlighting capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Aptean GenomeQuest (formerly GenomeQuest) Enterprise biological IP search platform providing comprehensive sequence-domain searching across 694+ million patent and non-patent sequences. Used by pharmaceutical and biotechnology companies, government patent offices, and IP law firms for prior art, novelty, freedom-to-operate, and patent validity analysis. Features include Enhanced Keyword in Context and SEQ ID Highlighting.

Quantifiable outcome

• 694+ million sequences in database

Named customers25 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Others

• WIPO PATENTSCOPE: WIPO PATENTSCOPE is the international patent application's global search portal operated by the World Intellectual Property Organization. It is an adjacent ecosystem participant: a free public search tool that patent offices (including GenomeQuest customers) use alongside commercial platforms.

Direct peers

• Minesoft: Minesoft provides PatentHub, PatBase, and MinePat enterprise patent search solutions serving patent attorneys, examiners, and corporate IP teams. It is a direct enterprise peer to GenomeQuest in the IP prior-art search category.
• Questel: Questel offers Orbit Intelligence, an enterprise patent search and analytics suite directly comparable to GenomeQuest's biological IP search capabilities. Both serve IP attorneys, patent offices, and life sciences R&D teams with subscription-based prior-art and freedom-to-operate tools.
• PatSnap: PatSnap is an AI-powered IP and R&D intelligence platform covering patents, sequences, and innovation analytics. It competes directly with GenomeQuest in pharma/biotech IP workflows and adds an emerging AI/ML layer that overlaps with GenomeQuest's prior-art and sequence-search use cases.

Emerging players

• SureChem (Digital Science): SureChem (part of Digital Science) provides chemical patent search and structure-based IP analytics. It is an emerging player in the IP search market that overlaps with GenomeQuest's life sciences patent search focus, particularly for chemistry-adjacent biotech IP.
• GeneCards: GeneCards is a comprehensive bioinformatics database of human genes maintained by the Weizmann Institute. It is an emerging, niche bioinformatics player adjacent to GenomeQuest's biological information focus, but does not target the IP/patent workflow directly.
• NCBI BLAST: NCBI BLAST is the public-domain standard for biological sequence similarity search maintained by the National Library of Medicine. It is not focused on patent prior-art, but represents the baseline sequence search tool against which GenomeQuest's IP-enriched patent/non-patent corpus competes.

Broad incumbents

• Clarivate: Clarivate is the dominant IP intelligence and scientific analytics platform (Derwent World Patents Index, PatentSight, Cortellis). It is a broad incumbent that competes with GenomeQuest across patent prior-art search and biotech IP analytics, but at significantly larger scale and a broader portfolio.
• CAS (Chemical Abstracts Service): CAS, a division of ACS, provides SciFinder-n and related scientific information platforms with deep coverage of chemical, biological, and patent literature. It overlaps with GenomeQuest in serving pharma/biotech IP professionals searching large scientific corpora for prior art.
• LexisNexis PatentAdvisor: LexisNexis IP (PatentAdvisor, PatentSight via Clarivate partnership, TotalPatent) provides patent search and analytics solutions to IP law firms and patent offices. It overlaps with GenomeQuest in freedom-to-operate, validity, and prior-art search workflows.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/GenomeQuest
• Facebookfacebook.com/gqlifesciences
• LinkedInlinkedin.com/company/gqlifesciences

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GQ Life Sciences